Pfizer Stock: 3.41% Decline Following Revenue Forecast Adjustment
Pfizer's stock closed down 3.41% at $25.53 on Tuesday at the New York Stock Exchange, following an announcement of adjusted revenue targets. The American pharmaceutical company has lowered its 2025 guidance and revealed less dynamic prospects for 2026 than expected. This decline occurred in a slightly bullish American market context, with the S&P 500 gaining 0.36% in the same session.
Significant Trading Volume Accompanies Decline
The stock contracted amidst a significant trading volume, with 110.9 million shares traded, representing 1.95% of the group's market capitalization. This intensity of transactions reflects a rapid market response to the company's financial announcements. Over a longer period, the performance remains moderate: the stock has only shown an increase of 0.79% over the past week and 1.11% over the past year, a trajectory that lags behind that of the S&P 500, which has gained 18.33% over twelve months. This divergence in performance underscores the relative underperformance of the pharmaceutical stock compared to the American benchmark index.
Revised Revenue Targets for 2025 and 2026
Pfizer has revised its 2025 revenue target to approximately $62 billion, thereby tightening its initial range of $61 to $64 billion announced earlier in the year. More significantly, the group anticipates a decline in its activity next year, with revenues expected between $59.5 and $62.5 billion for 2026. This disappointing outlook is largely due to an expected decline in Covid-19 related products (Paxlovid and Cominarty), which are projected to generate only $5 billion in 2026 compared to $6.5 billion in 2025. Additionally, there is an annual impact of about $1.5 billion due to the loss of exclusivity on certain major products, confirming the structural challenges the group faces in the coming years. Diluted and adjusted earnings per share are also expected to decline, moving from a range of $3 to $3.15 in 2025 to $2.80 to $3 in 2026.
Operational Expenses and R&D Investments
On the operational front, administrative expenses are expected to decrease from $13.1-14.1 billion in 2025 to $12.5-13.5 billion in 2026, while research and development expenditures are set to slightly increase from $10-11 billion to $10.5-11.5 billion. This realignment of expenses illustrates the group's cost realignment strategy while maintaining investments in innovation. Despite this short-term retreat, growth prospects post-loss of exclusivity remain at the core of the laboratory's strategy.
